Drug regulator's nod sought for phase-3 study of intranasal Covid vaccine in 5-18 age group

Drug regulator's nod sought for phase-3 study of intranasal Covid vaccine in 5-18 age group iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in phase 1, 2 and 3 clinical trials with successful results, a release from the vaccine-maker said. https://ift.tt/vKizFwf